Long-acting reversible contraception represents the most effective category of reversible contraception available, yet it remains underutilized in clinical practice - in part due to persistent misconceptions, in part due to provider knowledge gaps, and in part because contraception counseling is deprioritized in practices that do not consider it a core service. For providers serving reproductive-age women in a metabolic health, weight loss, or hormone optimization setting, LARCs are a clinically relevant and frequently ideal contraceptive option. This article provides an up-to-date clinical overview of the available LARC options, their appropriate use in the patient populations most likely to be in your practice, and the counseling points that matter most.
WHAT QUALIFIES AS A LARC
Long-acting reversible contraception refers to contraceptive methods that provide highly effective protection for an extended period - typically three to ten years or longer - without requiring ongoing patient action. They are reversible in that fertility typically returns promptly after removal. The two primary categories are intrauterine devices and subdermal implants.
Intrauterine devices are small, T-shaped devices inserted into the uterine cavity by a trained provider. They are available in two types - hormonal and non-hormonal. Hormonal IUDs release low doses of levonorgestrel locally within the uterus. Non-hormonal IUDs use copper as the active contraceptive agent. The subdermal implant - marketed in the United States as Nexplanon - is a single flexible rod approximately the size of a matchstick that is inserted just beneath the skin of the inner upper arm and releases etonogestrel continuously.
HORMONAL IUDs: UPDATED EFFICACY AND DURATION DATA
Several hormonal IUD options are currently available in the United States, each with different progestin doses, physical sizes, and approved durations of use. Understanding the differences between them allows for more individualized patient counseling.
Mirena releases 20 micrograms of levonorgestrel per day initially, declining over time, and is FDA-approved for 8 years of use. It is the most established hormonal IUD in the US market and has the largest evidence base. Many patients on Mirena experience significantly reduced menstrual bleeding or amenorrhea, which is a therapeutic benefit for patients with heavy periods or dysmenorrhea.
Liletta is approved for 8 years of use and was specifically studied in a broader patient population including nulliparous women and higher-BMI patients, making its efficacy data particularly relevant for the metabolic health practice setting.
Kyleena releases a lower initial dose of levonorgestrel - 17.5 micrograms per day - and is approved for 5 years. Its smaller size makes it a consideration for nulliparous patients or those with a smaller uterine cavity, though size alone should not be the determining factor in device selection.
Skyla is the smallest hormonal IUD available and releases 14 micrograms of levonorgestrel per day, approved for 3 years. It is specifically marketed for nulliparous patients due to its size but provides shorter duration coverage.
All hormonal IUDs work primarily through local effects on the endometrium and cervical mucus rather than through systemic hormone suppression. Ovulation is typically maintained in most users, which is clinically relevant for patients who are concerned about hormonal effects on their cycle or who are also receiving BHRT - systemic levonorgestrel levels from an IUD are substantially lower than those from oral hormonal contraceptives.
THE COPPER IUD: A HORMONE-FREE OPTION
The copper IUD - Paragard in the United States - is the only highly effective non-hormonal reversible contraceptive available. It works through the spermicidal effect of copper ions in the uterine cavity and is approved for up to 10 years of use, though evidence supports efficacy well beyond the labeled duration.
The copper IUD is an important option for several patient populations commonly encountered in metabolic health and hormone practices. Patients who prefer to avoid all exogenous hormones - including those who have had adverse experiences with hormonal contraception - are ideal candidates. Patients on BHRT who are concerned about potential interactions between hormonal contraception and their hormone therapy regimen benefit from a non-hormonal option that eliminates this concern entirely. Patients who cannot use estrogen-containing contraception due to cardiovascular risk factors or migraine with aura have access to highly effective contraception without the hormonal considerations that limit other options.
The most significant counseling point for the copper IUD is its effect on menstrual bleeding. Many patients experience heavier periods and increased cramping with the copper IUD, particularly in the first several months after insertion. This is the most common reason for early removal and should be discussed clearly before insertion so patients have accurate expectations.
THE SUBDERMAL IMPLANT
Nexplanon is a single-rod etonogestrel-releasing implant inserted subdermally in the inner upper arm under local anesthesia. It is approved for 3 years of use and is among the most effective contraceptive methods available - with a failure rate of less than 0.1 percent in typical use.
The implant is an excellent option for patients who want highly effective contraception without the need for a uterine procedure, patients who have had difficulty with IUD insertion, or patients who want a method they do not have to think about for an extended period. It is also not affected by GLP-1-related changes in gastric motility, making it a strong option for patients on semaglutide or tirzepatide who need reliable contraception.
The primary counseling point for the implant is unpredictable bleeding patterns. Many patients experience irregular spotting, particularly in the first 6 to 12 months after insertion. A smaller proportion experience amenorrhea, which some patients find desirable and others do not. Patients who are not counseled on this in advance are more likely to request early removal for what is actually a normal and expected pattern.
LARC USE IN HIGHER-BMI PATIENTS
Higher-BMI patients are a significant and underserved population in contraceptive counseling. Oral contraceptive efficacy may be reduced at higher body weights due to altered pharmacokinetics. Emergency contraception - particularly levonorgestrel-based options - has documented reduced efficacy at higher body weights. LARCs are not affected by body weight or BMI in terms of contraceptive efficacy, making them a particularly valuable option for this population.
Insertion considerations in higher-BMI patients are worth addressing proactively in clinical training. Adequate positioning and visualization during IUD insertion may require additional preparation in higher-BMI patients. For implant insertion, identifying the correct anatomical landmark for placement may require more careful palpation. Neither of these factors is a contraindication to LARC use - they are procedural considerations that experienced providers navigate routinely.
COMMON MISCONCEPTIONS WORTH ADDRESSING
Several persistent misconceptions about LARCs continue to affect uptake and should be addressed directly in patient counseling.
LARCs are not appropriate for women who have never been pregnant. This misconception has been formally addressed by major professional organizations including ACOG and the CDC, which state clearly that nulliparity is not a contraindication to IUD use. Clinical practice has moved significantly on this point, though some patients - and some providers - have not caught up with the evidence.
LARCs cause infertility. Fertility typically returns promptly after removal of any LARC. The hormonal IUD and the implant do not affect long-term fertility. The copper IUD has no effect on fertility at all. Patients who are planning future pregnancies are appropriate candidates for LARCs as a bridge contraceptive method until they are ready to conceive.
The hormonal IUD causes significant systemic hormone effects. The levonorgestrel released by hormonal IUDs acts primarily locally within the uterus. Systemic levonorgestrel levels from a hormonal IUD are substantially lower than those from oral contraceptive pills or the patch. Patients who have had adverse systemic effects from oral hormonal contraception may tolerate a hormonal IUD entirely differently ā€” and this distinction is worth making explicitly in the counseling conversation.
INTEGRATING LARC COUNSELING INTO YOUR PRACTICE
LARC counseling does not require a separate dedicated appointment in most cases. For providers in a weight loss or hormone optimization practice, the natural entry point is the contraception conversation that should already be part of the GLP-1 initiation visit. Mentioning LARCs as an option in that conversation - particularly their independence from oral absorption and their long-acting convenience - plants a seed that many patients will follow up on.
For providers who offer LARC insertions in their practice, the revenue and patient retention benefits are meaningful. Patients who receive their LARC from you, who are followed for weight management or hormone optimization, and who receive their annual well-woman care in your practice represent the kind of comprehensive, longitudinal patient relationship that drives practice stability and referral growth.
BOTTOM LINE
LARCs are the most effective reversible contraceptive option available, are not affected by body weight or oral medication absorption, and are appropriate for a broader patient population than many providers currently counsel. For providers serving reproductive-age women in metabolic health and hormone optimization settings, understanding and offering LARCs as part of a comprehensive contraceptive counseling approach is both clinically valuable and a meaningful differentiator for the practice.
